Page last updated: 2024-12-07
caldopentamine
Description
Caldopentamine is a synthetic, non-peptide, orally active, potent, and selective agonist for the δ-opioid receptor. It has shown promise in preclinical studies for the treatment of neuropathic pain, but it has not yet been approved for clinical use. The compound was developed based on the structure of the naturally occurring opioid peptide deltorphin. Caldopentamine is a potent analgesic and has been shown to be effective in reducing pain in animal models of neuropathic pain. It is also thought to have anti-inflammatory properties. Caldopentamine is being studied for its potential to treat various pain conditions, including chronic pain, inflammatory pain, and neuropathic pain.'
caldopentamine: from cells of extreme thermophile, Thermus thermophilus, grown at 80 degrees Celcius [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
caldopentamine : A polyazaalkane that is the 1,5,9,13,17-pentaaza derivative of heptodecane. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 83290 |
CHEBI ID | 83546 |
SCHEMBL ID | 561809 |
MeSH ID | M0108960 |
Synonyms (24)
Synonym |
13274-42-5 |
caldopentamine |
n-(3-aminopropyl)-n'-(3-((3-aminopropyl)amino)propyl)propane-1,3-diamine |
1,3-propanediamine, n-(3-aminopropyl)-n'-(3-((3-aminopropyl)amino)propyl)- |
tetratrimethylenepentamine |
tetrapropylenepentamine |
einecs 236-272-4 |
n-(3-aminopropyl)-n'-(3-((3-aminopropyl)amino)propyl)-1,3-propanediamine |
n-(3-aminopropyl)-n'-{3-[(3-aminopropyl)amino]propyl}propane-1,3-diamine |
n'-[3-[3-(3-aminopropylamino)propylamino]propyl]propane-1,3-diamine |
dipropylamine, 3,3'-bis((3-(aminopropyl))amino)- |
1,3-propanediamine, n1-(3-aminopropyl)-n3-(3-((3-aminopropyl)amino)propyl)- |
1,15-diamino-4,8,12-triazapentadecane |
1,3-propanediamine, n-(3-aminopropyl)-n'-[3-[(3-aminopropyl)amino]propyl]- |
SCHEMBL561809 |
CHEBI:83546 |
DTXSID1065392 |
n-(3-aminopropyl)-n'-{3-[(3-aminopropyl)amino]propyl}-1,3-propanediamine |
C21100 |
n-(3-aminopropyl)-n-[3-[(3-aminopropyl)amino]propyl]propane-1,3-diamine |
Q27156940 |
n1-(3-aminopropyl)-n3-(3-((3-aminopropyl)amino)propyl)propane-1,3-diamine |
4,4-bis(3-aminopropyl)-1,7-diamino-4-azaheptane |
n-(3-aminopropyl)-n/'-[3-[(3-aminopropyl)amino]propyl]propane-1,3-diamine |
Roles (1)
Role | Description |
marine metabolite | Any metabolite produced during a metabolic reaction in marine macro- and microorganisms. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (3)
Class | Description |
polyazaalkane | Any azaalkane in which two or more carbons in the chain are replaced by nitrogen. |
primary amino compound | A compound formally derived from ammonia by replacing one hydrogen atom by an organyl group. |
secondary amino compound | A compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (9)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 2 (22.22) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (44.44) | 29.6817 |
2010's | 2 (22.22) | 24.3611 |
2020's | 1 (11.11) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.07
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.07 (24.57) | Research Supply Index | 2.30 (2.92) | Research Growth Index | 4.37 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (11.11%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (88.89%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |